New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 21, 2012
10:00 EDTBEAV, THLD, PXD, LINE, BIIB, YUM, RPRX, MPLX, INFI, BRFS, WAIR, RLGY, LNCO, CELGOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: BE Aerospace (BEAV) initiated with an Outperform at Imperial Capital... BRF Brasil Foods (BRFS) initiated with a Buy at Citigroup... Biogen (BIIB) initiated with a Buy at Brean Capital... Celgene (CELG) initiated with a Buy at Brean Capital... Infinity Pharmaceuticals (INFI) initiated with an Outperform at RBC Capital... LINN Energy (LINE) initiated with a Neutral at Goldman... LINN Energy (LINE) initiated with an Outperform at RW Baird... LinnCo (LNCO) initiated with a Buy at UBS... LinnCo (LNCO) initiated with a Neutral at Credit Suisse... MPLX (MPLX) initiated with a Buy at Citigroup... Matrix Service (MTRX) initiated with a Buy at DA Davidson... Pioneer Natural (PXD) initiated with a Buy at Citigroup... Realogy (RLGY) initiated with a Neutral at Citigroup... Repros Therapeutics (RPRX) initiated with a Buy at Roth Capital... Threshold Pharmaceuticals (THLD) initiated with a Buy at Brean Capital... Wesco Aircraft (WAIR) initiated with an In-Line at Imperial Capital... Yum! Brands (YUM) initiated with an Outperform at Macquarie
News For BEAV;BRFS;BIIB;CELG;INFI;LINE;LNCO;MPLX;PXD;RLGY;RPRX;THLD;WAIR;YUM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
November 18, 2014
07:34 EDTCELGCelgene presents long-term OTEZLA data at ACR/ARHP meeting
Celgene announced that results from long-term efficacy and safety analyses of OTEZLA from the open-label phase of two PALACE phase III clinical trials were presented at the 2014 American College of Rheumatology/Association of Rheumatology Health Professionals annual meeting in Boston. OTEZLA is the Company’s oral, selective inhibitor of phosphodiesterase 4, approved by the U.S. FDA for the treatment of adult patients with active psoriatic arthritis and for the treatment of patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. In PALACE 1, 84 percent of patients who completed one year of 30 mg twice daily therapy continued to receive OTEZLA at two years. Improvements in efficacy measures observed at 52 weeks were sustained through 104 weeks of treatment. At week 104, among patients receiving OTEZLA 30 mg twice daily, the ACR20 response rate was 65.3 percent. ACR50 and 70 response rates were 34.0 percent and 19.6 percent, respectively, at week 104. Similar findings were observed in PALACE 4. In this trial, nearly 84 percent of DMARD-naïve patients who completed one year of OTEZLA 30 mg twice daily monotherapy continued to receive OTEZLA at two years. At week 104, among patients treated with OTEZLA 30 mg twice daily monotherapy, an ACR20, 50 and 70 response was reached by 61.4 percent, 40.7 percent and 19.2 percent of patients, respectively. In both PALACE 1 and PALACE 4, changes in other efficacy measures—including the HAQ-DI, which assesses improvements in physical function, and swollen and tender joint counts—were also generally sustained between weeks 52 and 104 with continued OTEZLA treatment. In PALACE 4, treatment with OTEZLA in patients with pre-existing enthesitis or dactylitis, two key manifestations of psoriatic arthritis, resulted in improvements in enthesitis and dactylitis that were sustained through 104 weeks of treatment.
November 17, 2014
07:16 EDTCELGMilken Institute--Faster Cures to hold a conference
Subscribe for More Information
07:05 EDTTHLDThreshold Pharmaceuticals announces TH-302, bevacizumab Phase 1/2 interim data
Threshold Pharmaceuticals announced interim data from a U.S. investigator-sponsored Phase 1/2 clinical trial of the investigational anticancer drug TH-302 in combination with bevacizumab for the treatment of glioblastoma, or GBM, the most lethal form of brain cancer. All patients in the study had previously progressed on single-agent bevacizumab, the only FDA-approved therapy for GBM patients with progressive disease following prior therapy. As reported by the investigator, in a total of 22 evaluable patients, best responses included one complete response and three partial responses for a response rate of 18%, and ten stable disease assessments for a clinical benefit rate of 64%; eight patients had progressive disease. Median progression-free survival was 2.8 months, and median overall survival was 4.6 months. In addition, the FDA, through its Office of Orphan Product Development, recently awarded Dr. Brenner a grant for a Phase 2 clinical trial of TH-302 for the treatment of GBM. His is one of 15 grants the FDA awarded in 2014 in order to boost the development of medical device, drug, and biological products for patients with rare diseases. According to the FDA, the grants are for clinical studies on safety and/or effectiveness of products that could either result in, or substantially contribute to, approval of the products.
November 14, 2014
18:05 EDTBEAVRelational Investors gives quarterly update on stakes
NEW STAKES: None. INCREASED STAKES: None. DECREASED STAKES: Mondelez (MDLZ), Manitowoc (MTW), Clean Harbors (CLH), and Hologic (HOLX). LIQUIDATED STAKES: Ingersoll-Rand (IR), B/E Aerospace (BEAV), Timken (TKR), Hess (HES), and NXP Semiconductors (NXPI).
17:07 EDTCELGSoros Fund Management gives quarterly update on stakes
Subscribe for More Information
07:14 EDTCELGAmerican College of Rheumatology is holding a meeting
2014 ACR/ARHP Annual Meeting is being held in Boston on November 14-19.
November 13, 2014
10:44 EDTRPRXOptions with decreasing implied volatility
Subscribe for More Information
10:42 EDTBIIBSummer Street chief scientific officer holds an analyst/industry conference call
Subscribe for More Information
07:10 EDTTHLDSociety for NeuroOncology to hold a meeting
Subscribe for More Information
November 12, 2014
10:34 EDTRPRXOptions with decreasing implied volatility
Options with decreasing implied volatility: RMTI RPRX KATE PNK CZR KING TSLA UBNT LOCO GNRC
08:13 EDTBIIBBoston Biotech to hold a conference
Subscribe for More Information
November 11, 2014
10:39 EDTRPRXOptions with decreasing implied volatility
Subscribe for More Information
10:20 EDTRLGYHigh option volume stocks
High option volume stocks: RLGY TWC LITB SPM ACRX JWN OCR CALL CST ERIC
07:07 EDTTHLDThreshold Pharmaceuticals receives FDA fast track designation for TH-302
Threshold Pharmaceuticals announced that the FDA granted Fast Track designation for TH-302, an investigational anticancer drug, for the treatment of previously untreated patients with metastatic or locally advanced unresectable soft tissue sarcoma, or STS. The FDA established the Fast Track designation process to facilitate the development and expedite the review of drugs intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs. An important feature of Fast Track is that the FDA may consider a "rolling review" of completed sections of the New Drug Application before the complete application is submitted.
November 10, 2014
10:17 EDTRPRXOptions with decreasing implied volatility
Options with decreasing implied volatility: RMTI ACHN RPRX ARCP SALE ZU KING UBNT KATE AWAY
09:31 EDTRLGYRealogy management to meet with JPMorgan
Subscribe for More Information
09:11 EDTBEAVBE Aerospace price target lowered to $84 from $97 at Sterne Agee
Sterne Agee cut its price target on BE Aerospace (BEAV) to reflect the cost of spinning off KLX. The firm keeps a Buy rating on BE Aerospace.
09:04 EDTRPRXRepros Therapeutics reports Q3 EPS 32c, consensus (39c)
Subscribe for More Information
07:36 EDTYUMPizza Hut to unveil major menu expansion, CNBC reports
Subscribe for More Information
07:19 EDTCELGCredit Suisse to hold a conference
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use